Michael Smith Foundation for Health Research Report issue

Foundation Phase 1 Phase 2

Organization Overview

First Clinical Trial
2019
NCT04021550
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Michael Smith Foundation for Health Research

Active Ingredients

Drugs in Phase 2 Trials (1)

tranexamic acid (cyklokapron) (1 trial)

Drugs in Phase 1 Trials (3)

alpha-lipoic acid (1 trial)

cellulose (1 trial)

telmisartan (micardis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Apnea (Phase 1)

Hematuria (Phase 2)

Sleep Apnea, Obstructive (Phase 1)

Sleep Apnea Syndromes (Phase 1)

Urinary Retention (Phase 2)

Urologic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4